
CHMP Recommends EU Approval of Vorasidenib for IDH1/2-Mutant Grade 2 Glioma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of vorasidenib (Voranigo) for the treatment of predominantly non-enhancing grade 2 astrocytoma or …